Cancer patients who respond to experimental drugs get continued access in safety study
NCT ID NCT02632994
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study offers continued access to experimental oral cancer drugs for patients who are already benefiting from them in a previous Lilly study. The main goal is to monitor long-term safety. Participants must not be in any other conflicting research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY2503029, LY3023414, LY3838915, LY3847429 (oral cancer drugs)
What this could lead to
If successful, this study helps ensure patients who are benefiting from experimental cancer drugs can keep taking them while safety data is collected.
What could go wrong
This is an extension study, not a new treatment test. It does not prove the drugs work for new patients, and long-term side effects are still being monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fort Wayne Oncology & Hematology
AVAILABLEFort Wayne, Indiana, 46804, United States
Contact Phone: •••-•••-••••
Contact
-
Sarah Cannon Cancer Center
AVAILABLENashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
Contact
-
UCLA Medical Center
AVAILABLETorrance, California, 90505, United States
Contact Phone: •••-•••-••••
Contact